176,516 Shares in DENTSPLY SIRONA Inc. $XRAY Acquired by Ieq Capital LLC

Ieq Capital LLC bought a new stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in the 2nd quarter, HoldingsChannel reports. The firm bought 176,516 shares of the medical instruments supplier’s stock, valued at approximately $1,873,000.

Other large investors have also recently added to or reduced their stakes in the company. Eurizon Capital SGR S.p.A. acquired a new position in DENTSPLY SIRONA in the fourth quarter worth approximately $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of DENTSPLY SIRONA during the 1st quarter worth $26,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of DENTSPLY SIRONA by 337.9% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,122 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in shares of DENTSPLY SIRONA by 119.1% in the 4th quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock worth $43,000 after acquiring an additional 2,051 shares during the last quarter. Finally, Performa Ltd US LLC raised its position in shares of DENTSPLY SIRONA by 116.1% during the fourth quarter. Performa Ltd US LLC now owns 4,250 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 2,283 shares during the period. 95.70% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Brian P. Mckeon bought 10,000 shares of DENTSPLY SIRONA stock in a transaction that occurred on Friday, June 12th. The stock was purchased at an average cost of $10.12 per share, for a total transaction of $101,200.00. Following the acquisition, the director owned 10,000 shares in the company, valued at $101,200. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Brian T. Gladden bought 9,985 shares of the business’s stock in a transaction on Monday, June 15th. The shares were purchased at an average cost of $10.02 per share, with a total value of $100,049.70. Following the transaction, the director owned 61,849 shares in the company, valued at approximately $619,726.98. The trade was a 19.25% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 35,160 shares of company stock valued at $351,179. Insiders own 0.46% of the company’s stock.

DENTSPLY SIRONA Trading Up 0.7%

Shares of NASDAQ XRAY opened at $10.97 on Wednesday. The firm has a market capitalization of $2.19 billion, a PE ratio of -3.99, a PEG ratio of 1.37 and a beta of 0.85. DENTSPLY SIRONA Inc. has a one year low of $9.40 and a one year high of $14.86. The company has a current ratio of 1.63, a quick ratio of 1.07 and a debt-to-equity ratio of 1.48. The business has a 50-day moving average price of $12.05 and a two-hundred day moving average price of $11.78.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.35 by $0.17. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The business had revenue of $898.00 million during the quarter, compared to analyst estimates of $889.93 million. During the same period in the prior year, the firm earned $0.52 earnings per share. The firm’s revenue was down 4.1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, analysts predict that DENTSPLY SIRONA Inc. will post 1.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

XRAY has been the subject of several analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DENTSPLY SIRONA in a report on Monday, August 3rd. UBS Group cut their price objective on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Barclays raised their target price on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a report on Monday. Barrington Research set a $15.00 target price on shares of DENTSPLY SIRONA in a research report on Monday, August 10th. Finally, Piper Sandler boosted their price target on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Wednesday, July 29th. Three research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $13.54.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.